Addressing Europe’s plasma deficit

Across the European Union approximately 300,000 patients with chronic conditions, such as haemophilia and severe immune-deficiency, depend on plasma-derived medicines, which can only be manufactured using donated blood plasma as there is no way to synthesise the raw material. However, with an estimated shortage of 5 million litres of plasma needed to manufacture these products, how can companies and regulators work to address the shortfall?

In this issue, pharmaphorum editor-in-chief Jonah Comstock sat down (virtually) with Takeda Pharmaceuticals’, Giles Platford, to find out.

Check out the full interview to learn more:

Watch video now